A Study of HY209 in Healthy Male Volunteers for Sepsis
Status:
Completed
Trial end date:
2020-06-12
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled single dosing, dose escalation phase I
clinical trial to investigate the safety/tolerability and pharmacokinetics of HY209 after
intravenous administration in healthy male volunteers